InChI=1S/C24H34O5/c1-22-9-7-16(25)11-15(22)4-5-18-21(22)19(26)12-23(2)17(8-10-24(18,23)28)14-3-6-20(27)29-13-14/h3,6,13,15-19,21,25-26,28H,4-5,7-12H2,1-2H3/t15-,16+,17-,18-,19-,21-,22+,23-,24+/m1/s1

Gamabufotalin(CS-6), a bufadienolide compound from toad venom, suppresses COX-2 expression through targeting IKKβ/NF-κB signaling pathway in lung cancer cells, suggests that CS-6 exhibits potential use in the treatment of COX-2-mediated diseases such as lung cancer.[1]
Gamabufotalin has been shown to strongly inhibit cancer cell growth and inflammatory response, CS-6 inhibits angiogenesis by inhibiting the activation of VEGFR-2 signaling pathways and CS-6 could be a potential candidate in angiogenesis-related disease therapy.[2]
Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma(MM) cells, it may be as a promising therapeutic agent in the treatment of MM.[3]

English website: Gamabufotalin
Japanese website: Gamabufotalin
Chinese website: Gamabufotalin

[1] Yu Z, Guo W, Ma X, et al. Mol Cancer, 2014, 13(1):1-14.
[2] Tang N, Shi L, Yu Z, et al. Oncotarget, 2015, 7(3):3533-47.
[3] Yu Z, Li T, Wang C, et al. Oncotarget, 2016, 7(13):15725-37.
[4] Ma X C, Zhang B J, Xin X L, et al. Nat Prod Commun, 2009, 4(4):179-84.